Načítá se...
Sunitinib re-challenge in advanced renal-cell carcinoma
Despite offering significant clinical benefits in advanced renal-cell carcinoma (RCC), the effectiveness of targeted therapies eventually declines with the development of resistance. Defining optimal sequences of therapy is therefore the focus of much current research. There is also evidence that tr...
Uloženo v:
| Vydáno v: | Br J Cancer |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Nature Publishing Group
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4453836/ https://ncbi.nlm.nih.gov/pubmed/24800947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.214 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|